Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Summary

Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors, announced its participation in two upcoming investor conferences. The company will engage in fireside chats at:

• The H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 11:00 a.m. ET in New York
• The 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 a.m. ET in New York

Webcasts of both events will be available on Sagimet's website, with replays accessible for 90 days after the live events. These conferences provide Sagimet an opportunity to showcase its progress in developing novel therapies targeting dysfunctional metabolic and fibrotic pathways.

News Market Reaction – SGMT

-2.70%

-2.70% Session move

In the trading session that priced this news, SGMT declined 2.70%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN MATEO, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) --  Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.

• A fireside chat at the H.C. Wainwright 26^th Annual Global Investment Conference in New York at 11:00 a.m. ET / 8:00 a.m. PT on September 10, 2024; and
  
• A fireside chat at the 2024 Cantor Global Healthcare Conference in New York at 9:10 a.m. ET / 6:10 a.m. PT on September 17, 2024.
  

Webcasts of each fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with archived replays available for 90 days following the live event.

About Sagimet Biosciences 

Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of MASH. FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. For additional information about Sagimet, please visit www.sagimet.com.

Contact:
Joyce Allaire 
LifeSci Advisors 
Jallaire@lifesciadvisors.com 

FAQ

When is Sagimet Biosciences (SGMT) presenting at the H.C. Wainwright Global Investment Conference?

Sagimet Biosciences (SGMT) is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024, at 11:00 a.m. ET / 8:00 a.m. PT in New York.

What is the date and time of Sagimet Biosciences' (SGMT) fireside chat at the Cantor Global Healthcare Conference?

Sagimet Biosciences (SGMT) will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on September 17, 2024, at 9:10 a.m. ET / 6:10 a.m. PT in New York.

How long will the webcasts of Sagimet Biosciences' (SGMT) investor conference presentations be available?

The webcasts of Sagimet Biosciences' (SGMT) investor conference presentations will be archived and available for 90 days following the live events on the company's website.

What type of inhibitors is Sagimet Biosciences (SGMT) developing?

Sagimet Biosciences (SGMT) is developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways.